<DOC>
	<DOCNO>NCT00028574</DOCNO>
	<brief_summary>RATIONALE : Gabapentin may effective relieve hot flash men prostate cancer . It yet know regimen gabapentin effective treat hot flash . PURPOSE : Randomized phase III trial compare different regimen gabapentin treat men prostate cancer .</brief_summary>
	<brief_title>Gabapentin Treating Hot Flashes Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness gabapentin manage hot flash men prostate cancer . - Determine response patient drug . - Determine toxicity drug patient . - Determine quality life patient treated drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord number hot flash per day ( 2-3 v 4-9 v 10 ) duration hot flash symptom ( less 9 month vs 9 month ) . Patients randomize one four treatment arm . All patient observe 7 day prior drug administration order collect baseline hot flash information . - Arm I : Patients receive oral gabapentin daily day 1-28 . - Arm II : Patients receive oral gabapentin daily day 1-7 twice daily day 8-28 . - Arm III : Patients receive oral gabapentin daily day 1-7 , twice daily day 8-14 , three time daily day 15-28 . - Arm IV : Patients receive oral placebo one three schedule correspond arm I-III . Patients arm may continue therapy gabapentin additional 8 week . Quality life assess baseline , day 28 , end additional 8 week . Patients follow 6 , 12 , 24 month . PROJECTED ACCRUAL : A total 220 patient ( 55 per treatment arm ) accrue study within 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Required characteristic : 1 . Men history prostate cancer receive receive androgen ablation therapy . 2 . Must stable dose hormone therapy past 4 week must plan discontinue hormone therapy throughout duration randomize phase ( 5 week ) . 3 . Presence hot flash ≥1 month prior study entry . 4 . Bothersome hot flash ( define occurrence ≥14 time per week sufficient severity make patient desire therapeutic intervention ) . 5 . Life expectancy ≥ 6 month . 6 . ECOG Performance Status ( PS ) 0 1 . 7 . ≥18 year age Contraindications : 1 . History renal insufficiency ( defined creatinine ≥1.5 x UNL last two year ) . 2 . Any following current ( ≤ 4 week ) plan therapy : Antineoplastic chemotherapy Androgens Estrogens Progestational agent 3 . History allergic adverse reaction gabapentin . 4 . Prior use gabapentin . 5 . Antidepressants ( use allow patient stable dose ≥1 month plan modify treatment next 5 week ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>hot flash</keyword>
</DOC>